David M. Weiner, MD

Scientific Advisory Board

Dr. Weiner has over 20 years of experience in the discovery and clinical development of novel therapeutics for neurological diseases. He started his career at ACADIA Pharmaceuticals, where, over a ten-year period, he held a series of discovery research and clinical development roles working on multiple CNS therapeutics, most notably pimavanserin approved for the treatment of Parkinson’s disease psychosis. He subsequently joined EMD Serono, in a late clinical development role, and ultimately headed early clinical development activities in neurology globally. Dr. Weiner has extensive experience in rare disease drug development, serving as CMO and Interim CEO for Proteostasis Therapeutics Inc., and most recently as CMO at aTYR Pharma. Dr. Weiner received his M.D. from the School of Medicine and Biomedical Sciences, SUNY at Buffalo, and was a Howard Hughes Medical Institute Research Scholar at the NIH in Bethesda. He trained in clinical neurology at New York Hospital, Memorial Sloan Kettering, Cornell Medical Center, and did a post-doctoral fellowship in Neuropharmacology at the University of Vermont. Dr. Weiner has authored over 30 scientific publications, has multiple patents, and serves on a number of clinical and scientific advisory boards, including the scientific advisory board of the Michael J. Fox Foundation for Parkinson Research.